Literature DB >> 8007740

Medicinal applications of cyclodextrins.

J Szejtli1.   

Abstract

Some cyclodextrins are produced industrially, and available in pharmaceutical quality, at reasonable prices. Their medicinal use means mainly--but not exclusively--the complexation of problematic drugs (poorly soluble, unstable, irritating, difficult to formulate substances). The CD complexation generally results in improved wettability, dissolution, and solubility; improved stability; reduced side effects; or in mildering of other undesired properties (e.g., bitter tastes, bad smells). CDs can be used advantageously practically in any drug forms: oral, rectal, pulmonary, external, ocular, etc. formulations. In oral solid and liquid formulations the chemical and physical stability and bioavailability, but particularly the role of absorption is improved. With appropriate highly soluble chemically modified CDs aqueous parenteral formulations can be prepared from poorly soluble drugs. Using CDs the transdermal penetration or nasal absorption of such drugs becomes possible, which earlier could not be administered through these ways. The direct therapeutic effects of CDs (or their derivatives) are demonstrated in several examples as well as the use of beta CD as vehicle in tabletting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8007740     DOI: 10.1002/med.2610140304

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  29 in total

1.  Dense gas processing of micron-sized drug formulations incorporating hydroxypropylated and methylated beta-cyclodextrin.

Authors:  Raffaella Mammucari; Fariba Dehghani; Neil R Foster
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

2.  Physico-chemical characterization and in vitro dissolution assessment of clonazepam-cyclodextrins inclusion compounds.

Authors:  Rakesh Patel; Nirav Purohit
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

3.  Cyclodextrin KnowledgeBase a web-based service managing CD-ligand complexation data.

Authors:  Eszter Hazai; Istvan Hazai; Laszlo Demko; Sandor Kovacs; David Malik; Peter Akli; Peter Hari; Julianna Szeman; Eva Fenyvesi; Edina Benes; Lajos Szente; Zsolt Bikadi
Journal:  J Comput Aided Mol Des       Date:  2010-06-03       Impact factor: 3.686

4.  Cyclodextrins as diethylstilbestrol carrier system: characterization of diethylstilbestrol-cyclodextrins complexes.

Authors:  E Núñez-Delicado; M Sojo; A Sánchez-Ferrer; F García-Carmona
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

5.  Organized polysaccharide fibers as stable drug carriers.

Authors:  Srinivas Janaswamy; Kristin L Gill; Osvaldo H Campanella; Rodolfo Pinal
Journal:  Carbohydr Polym       Date:  2013-01-11       Impact factor: 9.381

6.  Defining parameters of specificity for bioluminescent optogenetic activation of neurons using in vitro multi electrode arrays (MEA).

Authors:  Mansi Prakash; William E Medendorp; Ute Hochgeschwender
Journal:  J Neurosci Res       Date:  2018-08-28       Impact factor: 4.164

7.  Electrospray ionization mass spectrometric study of encapsulation of amino acids by cyclodextrins.

Authors:  R Ramanathan; L Prokai
Journal:  J Am Soc Mass Spectrom       Date:  1995-09       Impact factor: 3.109

Review 8.  Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.

Authors:  Amina Ben Mihoub; Ludivine Larue; Albert Moussaron; Zahraa Youssef; Ludovic Colombeau; Francis Baros; Céline Frochot; Régis Vanderesse; Samir Acherar
Journal:  Molecules       Date:  2018-08-02       Impact factor: 4.411

9.  Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies.

Authors:  M Narender Reddy; Tasneem Rehana; S Ramakrishna; K P R Chowdhary; P V Diwan
Journal:  AAPS PharmSci       Date:  2004-03-05

10.  Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins.

Authors:  L Hovgaard; H Brøndsted
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.